New cholesterol drug plus statin for heart attack patients with diabetes
Treatments studied
Part of Heart & circulation clinical trials.
This trial tests a new injectable cholesterol-lowering drug (called a PCSK9 inhibitor) combined with a statin for people with diabetes who have recently had a heart attack or unstable angina. It aims to see if this combination helps prevent future heart problems better than statins alone.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years old or older
- You were just in the hospital for a heart attack or unstable angina and had a heart catheterization
- You have diabetes
- You have never taken a statin (a cholesterol-lowering drug) before
- You do not have chronic liver disease or a liver tumor
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests whether starting strong cholesterol-lowering treatment early in the hospital can improve outcomes for people with acute coronary syndrome (a serious heart condition like a heart attack or unstable angina). It may help if you have high LDL cholesterol.
This trial tests whether a single injection of a PCSK9 inhibitor (a cholesterol-lowering medicine) can improve heart health after a stent procedure. It is for people who have a certain amount of fat buildup in their treated artery.
This study tests whether starting a cholesterol-lowering drug called a PCSK9 inhibitor soon after a heart attack can help prevent future blockages. If you had a heart attack, received a stent, and have other arteries with minor blockages, this trial may be for you.
This trial tests whether giving a powerful cholesterol-lowering drug (PCSK9 inhibitor) very early after a heart attack can help prevent further heart problems. It is for people who have had a recent heart attack and have blockages in more than one heart artery.
This trial studies whether starting a cholesterol-lowering medicine called a PCSK9 inhibitor early after a heart attack can improve heart health and outcomes. It focuses on people who had a recent heart-artery procedure to fix the blockage in the left anterior descending (LAD) artery.
This trial studies whether starting a PCSK9-blocking medicine early after a specific type of heart attack can improve heart outcomes. You may be eligible if you have a STEMI heart attack soon, are planning a procedure to open the blocked artery, and meet safety and pregnancy criteria.
Hear when a new Acute Coronary Syndromes trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.